HRMY - Harmony Biosciences Holdings, Inc.
Aurora Investment Counsel acquired a new position in Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 65,148 shares of the company's stock, valued at approximately $2,372,000. Harmony Biosciences accounts for approximately 1.2% of
Harmony Biosciences NASDAQ: HRMY highlighted record quarterly performance for its narcolepsy treatment WAKIX and outlined development plans across its orexin, epilepsy and pitolisant lifecycle-management programs during Piper Sandler's virtual CNS Symposium.
California State Teachers Retirement System raised its position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) by 40.9% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 57,928 shares of the company's stock after purchasing an additional 16,821 shares during
Healthcare's defensive demand is strengthening in 2026. BTSG, HRMY, UNH and NVCR stand out on improving earnings outlooks and steady sector momentum.
Stocks like SNX, AMP, HRMY and NWL are seeing price strength and have a high chance of carrying the momentum forward.
PLYMOUTH MEETING, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the Piper Sandler Virtual CNS Symposium on Thursday, August 13, 2026, at 1:30 p.m. ET.
Harmony Biosciences (NASDAQ: HRMY) reported second-quarter net revenue of $261.3 million, up 30% from the prior-year period and 21% sequentially, as sales of its narcolepsy treatment WAKIX rebounded from seasonal market-access pressures earlier in the year. The company reiterated its 2026 net revenue guidance of $1 billion to $1.04 billion. Net income for the quarter rose
Harmony Biosciences Holdings, Inc. has now elevated BP-205, its orexin-2 receptor agonist, to lead the pipeline. HRMY management has become even more specific about business development—exactly the kind of thing I thought was missing earlier. My updated valuation suggests most of the improvement is now reflected in the stock. I am, therefore, upgrading HRMY from Sell to Hold.
HRMY tops Q2 estimates as Wakix demand fuels 30% revenue growth. A growing pipeline, BP-205 progress and reaffirmed 2026 guidance add momentum.
Harmony Biosciences (HRMY) could produce exceptional returns because of its solid growth attributes.
Harmony Biosciences Holdings, Inc. (HRMY) Q2 2026 Earnings Call Transcript
Harmony Biosciences NASDAQ: HRMY reported second-quarter net revenue of $261.3 million, up 30% from the prior-year period and 21% sequentially, as sales of its narcolepsy treatment WAKIX rebounded from seasonal market-access pressures earlier in the year.
Harmony Biosciences Holdings, Inc. (HRMY) came out with quarterly earnings of $1.28 per share, beating the Zacks Consensus Estimate of $0.97 per share. This compares to earnings of $0.68 per share a year ago.
WAKIX® Net Revenue Grew 30% Year over Year to $261.3 Million for Second Quarter 2026; Estimated Average Patients Increased 450 to 8,950; Reiterates 2026 WAKIX Net Revenue Guidance of $1.0 Billion to $1.04 Billion Phase 1 SAD Data for BP-205 Demonstrate Favorable PK and Safety/Tolerability Profiles; Phase 1 MAD Data Expected in Q4 2026 BP-205 IND Open in US; Initiating Phase 1b Study in Sleep-Deprived Healthy Volunteers in Q3; Data Expected Early 2027 Initiating Phase 2 Trials for BP-205 in Mid-2027 to Evaluate Multiple CNS Indications Pitolisant GR NDA Accepted in July; Target PDUFA Date April 1, 2027 Pitolisant HD On Track for Phase 3 Topline Data in 2027 and Target PDUFA Date in 2028 Conference Call and Webcast Today at 8:30 a.m. ET PLYMOUTH MEETING, Pa.
With the Fed holding rates steady and Middle East tensions clouding market sentiment, ARW, PENN, GOOS and HRMY emerge as attractive value opportunities.
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Harmony Biosciences Holdings, Inc. (HRMY) or Acadia Pharmaceuticals (ACAD). But which of these two stocks presents investors with the better value opportunity right now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Harmony Biosciences, Invesco, GM, HPE and Quanex made the screen of low price-to-book stocks that also met multiple value metrics.
Harmony Biosciences (HRMY) is evolving from a single-product firm into a self-funded neuroscience platform, leveraging robust WAKIX growth. WAKIX posted 30% Q1 revenue growth, supporting a strong balance sheet with $710 million net cash and funding for pipeline expansion. HRMY trades at a deep valuation discount, reflecting market fears of WAKIX cash flow erosion post-2030 and underappreciated pipeline potential.
Harmony Biosciences (HRMY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.